drugset / Trial / NCT03731715
Carisbamate in Adult & Pediatric Subjects With Lennox-Gastaut Syndrome
Non-randomizedParallel-groupOpen-labelBasic science
Summary
This is an open-label, multi-center study of carisbamate in adult and pediatric subjects with LGS, with single- and multiple-dose PK assessments from Days 1 through 73. There will be a Screening Period of up to 28 days and a Treatment Period of 87 days.
Timeline
- Start
- 2019-02-07
- Primary completion
- 2022-05-23
- Completion
- 2022-06-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carisbamate | Small molecule | 30 mg | Oral |
| Subject | Carisbamate | Small molecule | 70 mg | Oral |
| Subject | Carisbamate | Small molecule | 100 mg | Oral |